Retatrutide Meta-30 Pen
Triple GIP/GLP-1/Glucagon Receptor Agonist - 30mg/3ml Pen
Indicative retail price · Not available for sale on this site
All products include a verification code for authenticity
PEPTIVA RETATRUTIDE META-30 PEN contains the world's first triple-receptor agonist peptide — a novel synthetic compound that simultaneously targets GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. This triple mechanism of action represents a paradigm shift in metabolic peptide research. By engaging all three receptor pathways, Retatrutide amplifies energy expenditure through glucagon receptor activation on hepatocytes and adipocytes, reduces appetite and slows gastric emptying via GLP-1 receptor signalling, and enhances glucose-dependent insulin secretion through GIP receptor activation. Phase II clinical trial data published in The New England Journal of Medicine demonstrated dose-dependent reductions in body weight of up to 24.2% at 48 weeks — the most significant results reported for any investigational metabolic compound to date. Retatrutide's unique pharmacological profile makes it an invaluable research tool for studying the interplay between incretin signalling and glucagon-mediated energy expenditure.
- Triple receptor agonist — first peptide to target GIP, GLP-1 and Glucagon simultaneously
- Industry-leading research data — up to 28.7% body weight reduction in TRIUMPH Phase 3 trials
- Energy expenditure — glucagon receptor activation increases metabolic rate
- Appetite & satiety — dual incretin signalling researched for reduced food intake
- Glucose & lipid control — studied for improved metabolic markers across all 3 pathways
- Most advanced metabolic peptide in research — paradigm shift over single/dual agonists
For Research Purposes Only
This product is supplied strictly for research and laboratory use only. Not intended for human consumption. Not for medical use. Not intended to diagnose, treat, cure, or prevent any disease.